HARROW, INC. - 8-K Filing
Harrow acquires global rights (excluding Japan) to TYRVAYA nasal spray from Viatris in $30M upfront deal with up to $70M in contingent milestone payments (Items: 1.01 Entry into a Material Definitive Agreement, 2.01 Completion of Acquisition or Disposition of Assets, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $HROW